Skip to main content

Table 2 Rate of on-treatment exacerbations for the UMEC/VI and TIO cohorts

From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

COPD-related exacerbation outcomes Number of events Rate (per 100 person-days) Rate ratio (95% CI) p value
UMEC/VI (N = 3929) TIO (N = 3929) UMEC/VI (N = 3929) TIO (N = 3929)
On-treatment period, mean (SD) [median] 150.1 (135.5) [90] 111.2 (116.6) [60] -
Total person-days 589 596 436 824
Exacerbations
 Overall 698 541 0.12 0.12 0.95 (0.84, 1.07) 0.473
 Moderate 476 392 0.08 0.09 0.90 (0.77, 1.06) 0.152
 Severe 222 149 0.04 0.03 1.10 (0.85, 1.35) 0.477
  1. CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol